Ivermectin
- Generic Name
- Ivermectin
- Brand Names
- Sklice, Soolantra, Stromectol
- Drug Type
- Small Molecule
- Chemical Formula
- C95H146O28
- CAS Number
- 70288-86-7
- Unique Ingredient Identifier
- 8883YP2R6D
- Background
Ivermectin is a semi-synthetic antiparasitic medication derived from avermectins, a class of highly-active broad-spectrum antiparasitic agents isolated from the fermentation products of Streptomyces avermitilis. Ivermectin itself is a mixture of two avermectins, comprising roughly 90% 5-O-demethyl-22,23-dihydroavermectin A (22,23-dihydroavermectin B) and 10%...
- Indication
Administered topically, ivermectin cream is indicated for the treatment of inflammatory lesions associated with rosacea. An over-the-counter ivermection lotion is commercially available and indicated for the topical treatment of head lice infestations in patients ≥6 months of age.
...
- Associated Conditions
- Ascariasis, Demodex Infestation, Enterobiasis, Filariasis caused by Loa Loa, Gnathostomiasis, Head Lice Infestation, Malaria, Myiasis, Onchocerciasis caused by Infection with Onchocerca volvulus, Rosacea, Scabies, Strongyloidiasis caused by Strongyloides Stercoralis Infection, Trichuriasis
- Associated Therapies
- -
Lymphatic Filariasis (LF) in Ivory Coast
- Conditions
- Interventions
- First Posted Date
- 2016-11-28
- Last Posted Date
- 2022-04-21
- Lead Sponsor
- University Hospitals Cleveland Medical Center
- Target Recruit Count
- 189
- Registration Number
- NCT02974049
- Locations
- 🇨🇮
Cote d'Ivoire, Abidjan, Côte D'Ivoire
Physiologically-based Pharmacokinetic Modeling of Ivermectin in Healthy Human Volunteers
- First Posted Date
- 2016-11-15
- Last Posted Date
- 2017-02-01
- Lead Sponsor
- University Hospital, Basel, Switzerland
- Target Recruit Count
- 12
- Registration Number
- NCT02963324
- Locations
- 🇨🇭
University Hospital Basel, Basel, Switzerland
Evaluation of the Inhibitory Effects of Topical Ivermectin on Markers of Rosacea Specific Inflammation.
- First Posted Date
- 2016-06-20
- Last Posted Date
- 2021-10-05
- Lead Sponsor
- University of California, San Diego
- Target Recruit Count
- 25
- Registration Number
- NCT02806414
- Locations
- 🇺🇸
UCSD Division of Dermatology, San Diego, California, United States
Comparative Safety and Efficacy of Two Treatments in the Treatment of Inflammatory Lesions of Rosacea
- Conditions
- Interventions
- First Posted Date
- 2016-06-09
- Last Posted Date
- 2021-11-02
- Lead Sponsor
- Padagis LLC
- Target Recruit Count
- 486
- Registration Number
- NCT02795117
Azithromycin - Ivermectin Mass Drug Administration for Skin Disease
- Conditions
- Interventions
- First Posted Date
- 2016-05-17
- Last Posted Date
- 2019-09-17
- Lead Sponsor
- London School of Hygiene and Tropical Medicine
- Target Recruit Count
- 1291
- Registration Number
- NCT02775617
- Locations
- 🇸🇧
Atoifi Adventist Hospital, Atoifi, Malaita, Solomon Islands
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
- Conditions
- Interventions
- Other: No systemic corticosteroidOther: No antiviral agent for COVID-19Other: No immune modulation for COVID-19Drug: Standard course macrolideOther: No antiviral agent for influenzaDrug: Local standard venous thromboprophylaxisOther: No immunoglobulinOther: No simvastatinOther: No cysteamineOther: No Immune Modulator for InfluenzaOther: No vitamin COther: No antiplateletProcedure: Clinician-preferred mechanical ventilation strategyOther: No renin-angiotensin system inhibitorOther: No endothelial modulatorDrug: CeftriaxoneDrug: Moxifloxacin or LevofloxacinDrug: Extended course macrolideDrug: Fixed-duration HydrocortisoneDrug: Five-days oseltamivirDrug: Lopinavir / RitonavirBiological: Convalescent plasmaDrug: Angiotensin converting enzyme inhibitorDrug: Nirmatrelvir/ritonavirDrug: Therapeutic dose anticoagulationProcedure: Protocolised mechanical ventilation strategyDrug: Interferon beta-1aDrug: Vitamin CDrug: SimvastatinDrug: AspirinDrug: EritoranDrug: CysteamineDrug: ImatinibDrug: Shock-dependent hydrocortisoneDrug: Ten-days oseltamivirDrug: P2Y12 inhibitorDrug: Angiotensin Receptor BlockersDrug: Conventional low dose thromboprophylaxisBiological: Delayed administration of convalescent plasmaDrug: Piperacillin-tazobactamDrug: HydroxychloroquineDrug: AnakinraDrug: ApremilastDrug: BaricitinibDrug: RemdesivirDrug: Fixed-duration higher dose HydrocortisoneDrug: Hydroxychloroquine + lopinavir/ritonavirDrug: Intermediate dose thromboprophylaxisDrug: Nirmatrelvir/ritonavir + remdesivirDrug: ARB + DMX-200Drug: CeftarolineDrug: Baloxavir MarboxilDrug: TocilizumabDrug: Amoxicillin-clavulanateDrug: Fixed-duration dexamethasoneDrug: Five-days oseltamivir + baloxavir marboxilDrug: Continuation of therapeutic dose anticoagulationDrug: IvermectinDrug: SarilumabDrug: Ten-days oseltamivir + baloxavir marboxil
- First Posted Date
- 2016-04-13
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- UMC Utrecht
- Target Recruit Count
- 20000
- Registration Number
- NCT02735707
- Locations
- 🇨🇦
Toronto Western Hospital, Toronto, Ontario, Canada
🇺🇸University of Illinois Health, Chicago, Illinois, United States
🇦🇺Bankstown-Lidcombe Hospital, Bankstown, New South Wales, Australia
Efficacy and Safety of High-dose Ivermectin for Reducing Malaria Transmission: A Dose Finding Study
- Conditions
- Interventions
- First Posted Date
- 2015-07-30
- Last Posted Date
- 2018-08-23
- Lead Sponsor
- Liverpool School of Tropical Medicine
- Target Recruit Count
- 141
- Registration Number
- NCT02511353
- Locations
- 🇰🇪
Jaramogi Oginga Odinga Teaching and Referral Hospital, Kisumu, Kenya
Repeat Ivermectin Mass Drug Administrations for Control of Malaria: a Pilot Safety and Efficacy Study
- First Posted Date
- 2015-07-28
- Last Posted Date
- 2019-01-04
- Lead Sponsor
- Colorado State University
- Target Recruit Count
- 2712
- Registration Number
- NCT02509481
- Locations
- 🇺🇸
Colorado State University, Fort Collins, Colorado, United States
🇧🇫Institut de Recherche en Sciences de la Santé, Bobo Dioulasso, Houet, Burkina Faso
Oral Ivermectin Versus Topical Permethrin to Treat Scabies in Children and Adults
- First Posted Date
- 2015-04-03
- Last Posted Date
- 2024-06-17
- Lead Sponsor
- University Hospital, Bordeaux
- Target Recruit Count
- 1092
- Registration Number
- NCT02407782
- Locations
- 🇫🇷
CHU de Dijon, Dijon, Bourgogne, France
🇫🇷CHG de Chalon sur Saône, Chalon sur Saône, Bourgogne, France
🇫🇷CHU de Rennes, Rennes, Bretagne, France
Development of Ivermectin for Alcohol Use Disorders
- Conditions
- Interventions
- First Posted Date
- 2014-01-27
- Last Posted Date
- 2018-08-08
- Lead Sponsor
- University of California, Los Angeles
- Target Recruit Count
- 11
- Registration Number
- NCT02046200
- Locations
- 🇺🇸
UCLA Addictions Laboratory, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.